LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Axsome Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERAXSM
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / AXSM COVERAGE

What’s moving Axsome Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Axsome Therapeutics, Inc.: Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

Axsome Therapeutics, Inc.: Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

The story matters when it changes Axsome Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease Transcript

Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease Transcript

The story matters when it changes Axsome Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025

Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025

Investors are testing whether Axsome Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript

Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript

Investors are testing whether Axsome Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest AXSM filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-04 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-03 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-02-23 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-15 · Period 2026-07-15SEC ↗8-KMaterial company eventFiled 2026-06-09 · Period 2026-06-05SEC ↗8-KMaterial company eventFiled 2026-06-09 · Period 2026-06-05SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-24 · Period 2026-04-24SEC ↗SCHEDULE 13G/AOfficial SEC filingFiled 2026-07-27SEC ↗
EARNINGS / QUARTERLY TRACKER

Axsome Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.